Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Emergent BioSolutions Inc.NYSE: EBS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $24.1M fell 7.3% year over year, ahead of the -8.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at -7.7% a year.

Context

  • Depreciation & amortization amounted to 13.2% of revenue in FY2025, up 3.1 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.3% holds above the trailing-twelve-month pace of -8.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.1M+2.6% QoQ
Last fiscal yearDec 2025
$98.3M-6.9% YoY
LTMMar 2026
$95.4M-8.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.3%——
1 year-6.9%——
3-year CAGR-7.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
98.3M USD
Year-over-year change
-6.9%
4-year CAGR
-4.5%

Depreciation & Amortization vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.8% is the 9th highest of 11, against a peer median of +9.5%.
  • Depreciation & amortization amounts to 14.1% of revenue for EBS, versus a peer median of 1.1%.
EBS Competitors
Depreciation & Amortization for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$95.4M USD-8.8%-7.7%14.1%
SNDLSNDL Inc.LTM Mar 2026CA$56.2M CAD-0.2%+5.9%6.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$33.03M USD+70.8%+14.3%6.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$2.41M USD-1.0%+34.3%0.8%
PRTAProthena Corporation plcLTM Mar 2026$2.31M USD+156.8%+70.7%4.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$577.25K USD+7.8%+2.8%0.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$528K USD-18.8%-38.4%1.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$481K USD+11.1%+11.1%—
CMPSCOMPASS Pathways plcLTM Mar 2026$179K USD-14.4%-13.2%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K USD+33.3%-34.1%—
ESPREsperion Therapeutics, Inc.LTM Mar 2026$106K USD+19.1%-40.6%0.0%
Peer median (excluding EBS) —+9.5%+4.4%1.1%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.